Compare Gilead Sciences, Inc. (GILD) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wix.Com Ltd — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Wix.Com Ltd trades at $74.13 (market cap $3.11B). The key difference: Gilead Sciences, Inc. is far larger — about 58.6× Wix.Com Ltd's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Wix.Com Ltd for 62 Days on average.
| GILD | WIX | |
|---|---|---|
Market Cap | $182.40B | $3.11B |
Volume | 4,469,821 | 809,286 |
Sector | Health | Technology |
52-Week High | $155.80 | $145.54 |
52-Week Low | $116.74 | $40.43 |
Typical Hold Time | 111 Days | 62 Days |
Enterprise Value | $205.46B | $4.19B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Wix stock trades at $72.97, down 1.27% today, amid a bearish technical signal and mixed earnings. Recent quarters show volatility with a Q1 2026 miss but a Q2 beat. Revenue growth is solid, reaching $1.99B in 2025, but profitability remains weak with a negative net income margin. The stock faces headwinds from a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026.
The outlook is cautious; analyst consensus is bullish with a $77 price target, but high valuation ratios and legal risks offset growth potential. Investors should weigh strong revenue trends against profitability challenges and near-term sentiment pressure from litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
